Payer Access Challenges and Overcoming Barriers to Optimal Care

Patients seeking oral acute myeloid leukemia (AML) treatments face significant access barriers through insurance coverage policies that often require extensive prior authorization processes, creating dangerous delays for those with rapidly progressive disease. Health care teams typically prepare insurance applications during first-cycle treatments to avoid interruptions in care, but approval processes can extend 2 to 3 weeks, during which patients with active leukemia cannot afford treatment delays. The requirement to demonstrate “failure” of intravenous hypomethylating agents before approving oral alternatives...